{"id":201,"date":"2026-06-07T16:53:03","date_gmt":"2026-06-07T14:53:03","guid":{"rendered":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/product\/bpc-157\/"},"modified":"2026-08-09T17:58:28","modified_gmt":"2026-08-09T15:58:28","slug":"bpc-157","status":"publish","type":"product","link":"https:\/\/wordpress-vsbv.srv1703136.hstgr.cloud\/de\/product\/bpc-157\/","title":{"rendered":"BPC-157"},"content":{"rendered":"

What is BPC-157?<\/h3>\n

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger protective protein (Body Protection Compound, BPC) with a molecular weight of approximately 40,000 Da, which was originally discovered and isolated from human gastric juice.<\/p>\n

This peptide is distinguished by extraordinary stability – it remains intact in human gastric juice for over 24 hours, which is a unique feature among bioactive peptides. Most standard growth factors (TGF-\u03b2, EGF) are rapidly degraded in the gastric environment, limiting their potential oral applications.<\/p>\n

BPC-157 has no sequence homology to other known peptides, which makes it a unique compound in the context of research on tissue regeneration and cytoprotection.<\/p>\n

Mechanism of action<\/h3>\n

The mechanism of action of BPC-157 is multidirectional and includes interactions with numerous molecular pathways:<\/p>\n

Modulation of the nitric oxide (NO) system<\/strong> \u2013 BPC-157 interacts with the NO system in a complex way: it induces the release of nitric oxide by activating the Src-caveolin-1-eNOS pathway, while modulating both inhibition (via L-NAME) and excessive stimulation (via L-arginine) nitric oxide synthase. This bidirectional regulation allows for the restoration of vascular homeostasis.<\/p>\n

Activation of the VEGFR2-Akt-eNOS pathway<\/strong> \u2013 The peptide activates the vascular endothelial growth factor receptor type 2 (VEGFR2), which leads to the stimulation of angiogenesis without the need for other ligands or shear stress.<\/p>\n

Effect on growth hormone receptor<\/strong> \u2013 Studies on rat tendon fibroblasts have shown that BPC-157 increases the expression of growth hormone receptor (GHR), which may contribute to regenerative effects in connective tissues.<\/p>\n

Interaction with the gut-brain axis<\/strong> \u2013 As a gastric-derived peptide, BPC-157 fits into the concept of the gut-brain axis, where peptides native to the gastrointestinal tract can exert both peripheral and central effects. The peptide affects the serotonergic and dopaminergic systems in specific areas of the brain.<\/p>\n

Cytoprotective effect<\/strong> \u2013 BPC-157 functions as a stabilizer of cell membranes (counteracting leaky gut syndrome) and a free radical scavenger, protecting cells against oxidative stress.<\/p>\n

Directions of scientific research<\/h3>\n

BPC-157 is the subject of intensive preclinical research, mainly in animal models. A 2025 systematic review identified 36 studies published between 1993 and 2024, of which 35 were preclinical studies.<\/p>\n

Research on tendon healing<\/p>\n

One of the most intensively researched areas is the effect of BPC-157 on tendon regeneration. In models of severed Achilles tendon in rats, BPC-157 accelerated the growth of tendon explants, increased the migration of tendon fibroblasts, and improved cell survival under conditions of oxidative stress (H\u2082O\u2082). Biomechanical tests showed increased tensile strength, Young’s modulus and improved functional gait indicators.<\/p>\n

Muscle regeneration research<\/p>\n

In muscle injury models (quadriceps transection, gastrocnemius injury), BPC-157 stimulated early collagen organization, egr-1 gene expression and nab2 repressor, leading to accelerated healing. The peptide also showed the ability to restore blood flow in ischemic muscles by stimulating angiogenesis.<\/p>\n

Ligament and bone research<\/p>\n

Preclinical studies also include models of ligament damage and bone fractures. BPC-157 improved the structural and biomechanical parameters of healing tissues, although the molecular mechanisms require further elucidation.<\/p>\n

Gastroenterological tests<\/p>\n

Due to its gastric origin, BPC-157 is intensively studied in the context of protecting the gastrointestinal mucosa. The peptide showed antiulcer activity in stress, ethanol, indomethacin and capsaicin-induced injury models. Clinical trials have been conducted in inflammatory bowel disease (IBD), although full results have not yet been published.<\/p>\n

Cardiovascular research<\/p>\n

BPC-157 is being studied for protecting the heart from damage, preventing arrhythmias, and modulating thrombosis. In models of large vessel occlusion, the peptide activated collateral circulation, preventing multi-organ failure.<\/p>\n

Neurological examinations<\/p>\n

In the context of the gut-brain axis, BPC-157 is being studied for anxiolytic, antidepressant, anticonvulsant effects and counteracting symptoms of catalepsy and schizophrenia-like models in rats. The peptide influenced the release of serotonin in specific areas of the brain, mainly in the nigrostriatal system.<\/p>\n

Spinal cord injury research<\/p>\n

Preliminary preclinical studies are examining the potential of BPC-157 to reduce inflammation and support nerve regeneration after spinal cord compression injuries.<\/p>\n

Scientific context<\/h3>\n

BPC-157 fits into the concept of gastric cytoprotection proposed by Andr\u00e9 Robert, according to which peptides native to the gastrointestinal tract can exert a wide range of protective effects on various organs. This is consistent with the observation that compounds with potent antiulcer activity often also have beneficial effects in other tissues.<\/p>\n

Compared to other regenerative peptides (such as TB-500<\/a>\/Thymosin \u03b24 or collagen peptides), BPC-157 stands out:<\/p>\n